Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

IGC Pharma, Inc. Common Stock (NY: IGC )

0.3439 +0.0125 (+3.77%)
Streaming Delayed Price Updated: 2:19 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 Next >
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
Via Benzinga
IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
IGC stock results show that IGC Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025. 
Via InvestorPlace
IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024
IGC stock results show that IGC Pharma met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Hedge Fund Settles At $2.25M With SEC For Exposed Short Seller Deal, 2 Cannabis Stocks Affected
Discover how Anson Funds settled with the SEC for $2.25M over an undisclosed collaboration with short seller impacting cannabis stocks 
Via Benzinga
Topics Cannabis Regulatory Compliance
Exposures Cannabis Legal Regulatory
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings
6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings 
Via News Direct
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news for Wednesday morning! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
Via Benzinga
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
--News Direct-- 
Via News Direct
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research
Via Benzinga
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... 
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
Via Benzinga
IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1
--News Direct-- 
Via News Direct
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses
IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why IGC Pharma Stock Is Moving Higher
IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... 
Via Benzinga
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
IGC Pharma partners with University of Los Andes, to leverage AI for improving Alzheimer's disease treatment and clinical trial efficiency. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cannabis Based Pain Relief Solution Receives European Patent Approval
IGC Pharma, Inc. (NYSE American: IGC) has been granted European Patent No. 3193862 by the European Patent Office for its innovative "Cannabinoid Composition and Method for Treating Pain." 
Via Benzinga
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.